Rapid SARS-CoV-2 Antigen Detection Assay in Comparison with Real-time RT-PCR Assay for Laboratory Diagnosis of COVID-19 in Thailand
Overview
Authors
Affiliations
Background: The Coronavirus disease 2019 (COVID-19) pandemic continues to spread across the world. Hence, there is an urgent need for rapid, simple, and accurate tests to diagnose severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Performance characteristics of the rapid SARS-CoV-2 antigen detection test should be evaluated and compared with the gold standard real-time reverse transcription-polymerase chain reaction (RT-PCR) test for diagnosis of COVID-19 cases.
Methods: The rapid SARS-CoV-2 antigen detection test, Standard™ Q COVID-19 Ag kit (SD Biosensor®, Republic of Korea), was compared with the real-time RT-PCR test, Allplex™ 2019-nCoV Assay (Seegene®, Korea) for detection of SARS-CoV-2 in respiratory specimens. Four hundred fifty-four respiratory samples (mainly nasopharyngeal and throat swabs) were obtained from COVID-19 suspected cases and contact individuals, including pre-operative patients at Siriraj Hospital, Bangkok, Thailand during March-May 2020.
Results: Of 454 respiratory samples, 60 (13.2%) were positive, and 394 (86.8%) were negative for SARS-CoV-2 RNA by real-time RT-PCR assay. The duration from onset to laboratory test in COVID-19 suspected cases and contact individuals ranged from 0 to 14 days with a median of 3 days. The rapid SARS-CoV-2 antigen detection test's sensitivity and specificity were 98.33% (95% CI, 91.06-99.96%) and 98.73% (95% CI, 97.06-99.59%), respectively. One false negative test result was from a sample with a high real-time RT-PCR cycle threshold (Ct), while five false positive test results were from specimens of pre-operative patients.
Conclusions: The rapid assay for SARS-CoV-2 antigen detection showed comparable sensitivity and specificity with the real-time RT-PCR assay. Thus, there is a potential use of this rapid and simple SARS-CoV-2 antigen detection test as a screening assay.
Establishment and application of national reference panels for SARS-CoV-2 antigen detection kit.
Ma T, Liu D, Lyu K, Gao T, Shi D, Zhao L Biosaf Health. 2025; 5(6):326-330.
PMID: 40078745 PMC: 11895040. DOI: 10.1016/j.bsheal.2023.10.002.
Kim M, Lee K, Kim S, Kim H, Han J, Kim H Front Neurol. 2025; 15():1488529.
PMID: 39839862 PMC: 11746089. DOI: 10.3389/fneur.2024.1488529.
Diagnostic and Prognostic Value of SCUBE-1 in COVID-19 Patients.
Ozer V, Gonenc Cekic O, Bulbul O, Aydin D, Bulut E, Aksoy F West J Emerg Med. 2024; 25(6):975-984.
PMID: 39625772 PMC: 11610722. DOI: 10.5811/westjem.18586.
Reinoso Schiller N, Baier C, Dresselhaus I, Loderstadt U, Schluter D, Eckmanns T Antimicrob Steward Healthc Epidemiol. 2024; 4(1):e125.
PMID: 39257431 PMC: 11384156. DOI: 10.1017/ash.2024.371.
Sannasi Chakravarthy S, Bharanidharan N, Vinothini C, Vinoth Kumar V, Mahesh T, Guluwadi S BMC Med Imaging. 2024; 24(1):206.
PMID: 39123118 PMC: 11313131. DOI: 10.1186/s12880-024-01394-2.